… Cancer Center Hospital. Eighty-two of these patients had lung cancer, and all patients with
lung cancer … patients' charts and clinical records. At the time of data analysis, almost all of the …

… genetic factors and clinical outcome in Japanese non-small-cell lung cancer (NSCLC)
patients treated with gefitinib. Ninety-eight NSCLC patients who had been treated with gefitinib, …

… Cancer patients' reluctance to disclose their emotional distress to their physicians: a study of
Japanese patients with lung cancer… only included Japanese patients with lung cancer. Thus, …

… The test of PD-L1 expression has been covered by insurance from February 2017 in Japan,
but all of the early death patients in this study died by November 2016. In only 1 patient, the …

… more effective in Asian patients than in patients of other … lung disease associated with the
administration of gefitinib is also more common among Japanese patients than among patients …

… These findings might be important in the future trial involving resectable lung cancer when
we stratify the patients by prognostic factors. In the present study, the histologic category as …

… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …

… growth factor (VEGF) in Japanese patients with small cell lung cancer (SCLC). Materials …
assay in 45 patients with SCLC before treatment and in 38 patients with benign pulmonary …

… Medical records of 91 young (40 years of age or younger) and 3,221 older (more than 40
years of age) Japanese patients with lung cancer were reviewed to compare smoking habits, …

… We investigated the incidence of ILD in Japanese patients … Japanese patients receiving
erlotinib are scarce. Herein, we examined the incidence and pattern of ILD in Japanese patients …